An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Vonaprument: Form: solution for injection; Route of Administration: IVT injection
Study summary
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.
Exclusion Criteria:
* Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.
Primary outcome measure(s)
Number of Participants with Treatment Emergent Adverse Events — Through Month 24
Trial sites (7)
Facility
City
Region
Status
Retina Group of Florida
Sarasota
Florida
Retina Vitreous Associates of Florida
St. Petersburg
Florida
Cumberland Valley Retina Consultants
Hagerstown
Maryland
Mid Atlantic Retina Specialists
Hagerstown
Maryland
Retina Research Institute at New England Retina Consultants
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.